Chelonian Conservation And Biology

Vol. 17No.2 (2022) | https://www.acgpublishing.com/ | ISSN - 1071-8443

DOI:doi.org/10.18011/2022.04(1) 1441.1451

UNDERSTANDING THE TRANSMISSION PATTERNS OF COVID-19

Mohammed Saad S Aldosari, Hamad Ahmad Al Saigh, Hamad Ibrahim Al Ghareeb, Saad Awad Almarzzouk, Naif Saeed Al Shahrani, Binshalhob, Zaid Abdulaziz A, Nasser Faleh Alghatani, Ibrahim N M Aldhuwailea, Bandar Saleh Rashed Al Khara, Abduaziz Rashed Zaid Bin Gannam, Ali Abdulaziz Almuslim

Abstract:

The study of the occurrence and distribution of COVID-19 highlights the significant impact of age and the presence of other medical conditions on the severity of the illness and the likelihood of death. Older persons, especially those aged 70 and beyond, are at a much elevated risk of experiencing serious disease and mortality. Coexisting medical conditions including hypertension, diabetes mellitus, and cardiovascular illnesses worsen the results of COVID-19, emphasizing the need of customized preventative measures and integrated healthcare treatments. The variability in the virus's ability to propagate, as shown by calculations of the reproductive number (R0), highlights the ever-changing nature of its transmission and the need for flexible public health interventions. Discrepancies in medical facilities and socioeconomic variables throughout the globe lead to different results in various nations and areas. This highlights the need of fair access to resources and well-coordinated international collaboration. Gaining a comprehensive understanding of the epidemiological characteristics of COVID-19 is essential for developing policies and actions based on solid research, with the aim of reducing its effect and eventually ending the pandemic.

Key Words: Transmission, COVID-19, Epidemiology, reproductive number, Infection, medical facilities.

Introduction:

In December of 2019, an outbreak of pneumonia of unknown origin emerged in Wuhan City, located in Hubei Province, China. Several initial patients had visited a wet seafood market where various other wildlife species were also sold. Upon virus isolation from these patients and subsequent molecular analysis, it was determined that the pathogen was a novel coronavirus (CoV), initially designated as 2019-nCoV, and later officially named COVID-19 by the World Health Organization (WHO). While a study group of the International Committee on Taxonomy of Viruses (ICTV) proposed the name SARS-CoV-2, its official approval is pending. This new CoV represents the seventh member of the Coronaviridae family known to infect humans. The rapid increase in confirmed cases led to the WHO declaring this outbreak a Public Health Emergency of International Concern (PHEIC) on January 30, 2020 [1].

Coronaviruses (CoVs) encompass a genetically diverse group of viruses that infect a wide range of host species, including birds and mammals. Many CoVs cause respiratory and intestinal infections in both animals and humans. CoVs gained global attention in 2002–2003 when clusters of "atypical pneumonia" were reported in Guangdong Province, subsequently spreading to Hong Kong. A novel CoV virus (SARS-CoV) was isolated by researchers in Hong Kong, leading to the renaming of the disease as severe acute respiratory syndrome (SARS). Due to international travel, the virus spread beyond Hong Kong, infecting over 8000 people in 26 countries with a case fatality rate of around 10%. This outbreak posed a significant public health threat and had a substantial negative impact on the economies of affected areas. Subsequent research revealed that SARS-CoV originated from bats and was transmitted to humans through an intermediate host, either Himalayan palm civets (Paguma larvata) or raccoon dogs (Nyctereutes procyonoides). Another notable CoV of animal origin is Middle East respiratory syndrome coronavirus (MERS-CoV), which has an even higher case fatality rate but is rarely transmitted between humans [2].

Bats serve as significant natural reservoir species for Alphacoronavirus and Betacoronavirus, harboring a wide range of SARS-like-CoVs. These bats are found across numerous provinces in China. Extensive research has been conducted on the genetic diversity and molecular evolution of these SARS-like-CoVs within their natural host species. In this review, we examine the current epidemiological insights into COVID-19, acknowledging the limited available data, and analyze the viral characteristics of 2019-nCoV in light of our understanding of previous SARS and MERS epidemics [3].

For more than 50 years, coronaviruses have been known to cause mild to moderate respiratory infections. Although these viruses have been isolated from a variety of animals, bats are generally accepted as the main natural coronavirus reservoirs. There are four human coronaviruses known to cause the common cold in humans: 229E, HKU1, NL63, and OC43. On the other hand, the identification of new coronaviruses, such MERS-CoV (2012) and SARS-CoV (2002), significantly altered our knowledge of this virus family. Nosocomial epidemics and severe acute respiratory illnesses were brought on by these viruses. In Wuhan, China, at the close of 2019, a new coronavirus that is currently known as SARS-CoV-2 (2019) unexpectedly surfaced. On January 31, 2020, the World Health Organization proclaimed the epidemic a Public Health Emergency of International Concern. The COVID-19 pandemic, which began to emerge on April 16, 2020, has spread over the world, resulting in over 2 million cases and over 137,000 deaths. We must now more than ever prioritize prevention and treatment strategies for coronavirus infections, given the significant impact this disease has recently had on our daily lives as a new group of respiratory diseases, characterized by higher rates of transmissibility, hospitalization, admissions to intensive care units, severity of illness, mortality, and so forth [4].

In conclusion, the discovery of new coronaviruses in recent years, such SARS-CoV and MERS-CoV, has profoundly changed our knowledge of these viruses and caused nosocomial epidemics and outbreaks of serious respiratory diseases. The COVID-19 pandemic began with the unexpected arrival of SARS-CoV-2 in Wuhan, China, at the end of 2019. Since then, the virus has spread around the world, resulting in millions of cases and a substantial death toll. The outbreak's designation as a Public Health Emergency of International Concern highlights how serious things have become. In light of COVID-19's unparalleled impact and its greater transmissibility and severity in comparison to other coronaviruses, preventative and treatment efforts must be given top priority. Comprehending the genetic variability and molecular progression of coronaviruses, specifically those borne by bats, is crucial for efficient epidemiological monitoring and mitigation strategies. In the future, reducing the effects of coronavirus infections and averting pandemics will require sustained research and international cooperation.

Epidemiology:

There are currently 75 995 confirmed cases as of February 20, 2020 (UTC+8), with 2239 fatalities in China (mainland: 75 891; Hong Kong: 68; Macao: 10; and Taiwan: 26). There are also 1200 confirmed cases, including eight fatal ones outside of China, across all five continents. Three phases can be distinguished roughly on the epidemiological curve [5].

The first case appeared in December 2019 and by January 13, 2020, there had been 41 confirmed cases in the first phase of the local outbreak, which was caused by exposure in the aforementioned food wholesale sector. According to epidemiological study, close contact had already resulted in person-to-person transmission during this phase. The virus rapidly multiplied and spread across hospitals (nosocomial infection) and among family members (close-contact transmission) during the second phase, which started on January 13. During this phase, the disease spread from Wuhan to other areas. The first case outside of China was originally recorded in Thailand on January 13, and it came from a visitor from Wuhan [6].

As of January 19, instances had spread throughout China, with 205 confirmed cases, outside of Wuhan in Beijing City and the Guangdong Province. 846 confirmed cases had been reported as of January 23, spanning 29 provinces and six international nations. This represents an approximately 20-fold increase from the first phase. Meanwhile, during the customary mass exodus for the Chinese New Year, Wuhan imposed a lockdown on the whole city, forcing more than 5 million people to evacuate. On January 26, the third phase began, accompanied by a sharp increase in cluster cases. Retrospective research by February 10 showed that 50–80% of all confirmed cases in various regions were clustered cases. By January 30, there had been 9826 confirmed cases, which prompted the World Health Organization to proclaim the pandemic a Public Health Emergency of International Concern. In around 1386 counties and districts in China, there were 44,730 confirmed cases and 16,067 suspected cases recorded as of February 11. There were only 441 confirmed cases outside of China, with one fatality in the Philippines [7].

On February 12, newly confirmed cases increased to 14,840, with 13,332 cases diagnosed just on the basis of clinical criteria in Hubei province as a result of a new clinical definition for diagnosis. By then, 25 countries had recorded 60,329 infections, a 1471-fold increase from the original figure. The number of confirmed cases outside of Hubei started to diminish on February

3, which seemed to mark a turning point in the epidemic. However, the exact causes of this decline are still unknown; they might have anything to do with the success of the Wuhan lockdown and other public health efforts, among other things [8].

Furthermore, a resounding majority of verified cases—85.8% out of 37,269—either lived in Wuhan, had traveled there, or had strong relationships with someone who had. Unfortunately, as of February 11, 1688, instances had been verified and examined, out of a total of 1716 medical staff members from 422 medical facilities. Of these, 23.3% were infected outside of Wuhan in other parts of Hubei province, while 64% were sick in Wuhan city. More research is necessary to determine the precise causes of the medical staff infection and the insufficiency of safety precautions. According to preliminary analyses of COVID-19 transmission patterns, 2019-nCoV's fundamental reproductive number (R0) is thought to vary between 1.4 and 3.9. In contrast, the R0 of SARS-CoV varied from 2.3 to 3.7 in the absence of treatments. Breban et al. examined 55 of the first 64 laboratory-confirmed cases and calculated the R0 of MERS-CoV to be between 0.50 and 0.92. Rapid diagnosis and efficient patient separation were implemented, and as a result, the R0 of SARS-CoV was lowered to less than 1, which helped to eventually contain the outbreak. It is imperative to acknowledge that a plethora of biological, socio-behavioral, and environmental factors can cause variations in R0 values, hence requiring a cautious interpretation [9].

Phenotyping of COVID-19:

The most common early signs of COVID-19 are fever, coughing, painful muscles, and trouble breathing. Some people may experience unusual symptoms like vomiting and diarrhea. However, the fact that at least one underlying medical condition affects 25.2% of patients complicates the disease's clinical presentation. Furthermore, the various stages of the epidemic have an impact on the general clinical features of COVID-19. Early-stage patients in the epidemic typically have a history of exposure to the seafood market, are older, and are more likely to be male. Clinically, they frequently have ground glass opacity or bilateral patchy shadows in the lungs. Compared to the latter period, the mortality rate during these early phases is significantly higher, ranging from 4.3% to 15%. Numerous reasons, such as a higher incidence of underlying medical disorders, enhanced virus pathogenicity during the early phase, or differences in sample sizes across phases, could be responsible for this higher mortality rate. Crucially, a sizable percentage of cases that are asymptomatic or subclinically symptomatic have been documented, which presents difficulties for screening initiatives that rely only on overt symptoms or temperature readings [10].

Age is not a barrier to COVID-19 infections, as cases have been documented in neonates. Between the ages of 30 and 69, there is a slight male predominance among confirmed cases. As of right now, there is no proof that pregnant women who are infected with COVID-19 may transmit the virus vertically into their uteri or that they are more vulnerable to the virus than non-pregnant adults. The COVID-19 pandemic persists despite a decline in new infections, potentially due to increased transmission risks brought on by Chinese nationals returning to the workforce and subsequent population migration. In China, the COVID-19 death rate is currently

2.9%, while it is 0.7% in other nations. Profoundly greater than the other provinces, Hubei province has the highest death rate (3.4%). In contrast, MERS-CoV had a mortality rate of 34.4%, whereas SARS-CoV had a case fatality rate of 9.6%. Nonetheless, 2019-nCoV is thought to be more contagious than MERS-CoV and SARS-CoV combined [11].

Virology:

The group of enclosed positive-stranded RNA viruses that includes coronaviruses. The coronavirus that causes COVID-19 is part of the Betacoronavirus group, which is in the same subgenus as the SARS virus and a few other bat coronaviruses, despite being in a separate clade. This information has been obtained through full-genome sequencing and phylogenetic analysis. This virus has been proposed for classification as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the International Committee on Taxonomy of Viruses' Coronavirus Study Group. The virus that causes Middle East respiratory syndrome (MERS) is unrelated to other beta coronaviruses. Bats are most likely the major source of SARS-CoV-2 due to their genetic similarities to two bat coronaviruses; however, it is still unclear if the virus is spread directly from bats or via an intermediary host [12].

Similar to SARS-CoV, SARS-CoV-2 uses the angiotensin-converting enzyme 2 (ACE2) as its cell entrance receptor. Through its spike protein's receptor-binding domain, SARS-CoV-2 interacts with ACE2. SARS-CoV-2 cell penetration is also significantly aided by the cellular protease TMPRSS2. Similar to other viruses, SARS-CoV-2 changes over time and most mutations do not affect the virus's ability to function. On the other hand, some variants have become known as variants of concern because of their quick appearance in populations and possible effects on clinical outcomes or transmission. The D614G mutation in the SARS-CoV-2 spike protein is one prominent variation that has taken center stage worldwide. Research indicates that as compared to the original D614 variant, the G614 variant shows increased replication and transmissibility, improved binding to ACE-2, and higher levels of infectiousness in the respiratory tract. It does not, however, seem to affect anti-spike antibody binding or be linked to an increased risk of hospitalization. Currently, the majority of circulating SARS-CoV-2 lineages—including additional variants of concern—have the G614 mutation. The CDC website provides data on the percentages of circulating variants of concern in the United States [12].

The B.1.1.7 lineage, commonly referred to as the Alpha variation or 20I/501Y.V1, was first discovered in the UK towards the end of 2020 and was associated with an increase in local infections. Compared to other circulating strains, this variant has over a dozen alterations, several of which are located within the spike protein. Since then, it has been found in a number of nations, including the US. According to several studies, the Alpha variety has greater secondary attack rates and is between 50 and 75 percent more transmissible than earlier strains. Although certain studies show longer viral RNA detection times and higher viral RNA levels in respiratory secretions, the precise mechanism underlying this increased transmissibility is yet unknown. Notably, N501Y, one of the mutations in the Alpha version, increases the infectivity of SARS-CoV-2 in animal models. Regarding the degree of illness linked to the Alpha variety, the results are conflicting; some research suggest a higher degree of illness, while others do not.

Nevertheless, there isn't any proof of a substantial immunity escape linked to this variation as of yet. Research has indicated that certain vaccinations continue to be effective against the Alpha version of COVID-19 and that serum from recipients of the vaccine maintains neutralizing activity against it. Further mutations in the spike protein of the Alpha form, such as E484K, which is linked to immunological escape, have been found through ongoing genomic study. A noteworthy mutation that impacts specific molecular tests that target the S gene is a loss in the spike protein at amino acids 69–70. This deletion has been seen in other variations as well, despite the fact that it has been utilized as a flag to identify the Alpha form [12].

Since its initial discovery in India in December 2020, the Delta variety—also referred to as the B.1.617.2 lineage or 20A/S:478K—has emerged as the most common form in a number of nations, including the US and the UK. Research indicates that the Delta variation is more contagious than the Alpha variant. In the UK, the percentage of SARS-CoV-2 infections linked to the Delta variant rose whereas those linked to the Alpha variant decreased. When compared to Alpha, the secondary home infection rate associated with Delta infection was significantly higher. The Delta variant was linked to a markedly higher household attack rate in a minor outbreak that occurred in the United States. Initial respiratory tract viral RNA levels were significantly greater with the Delta variant compared to the ancestral virus circulating in the early stages of the pandemic, according to preliminary data from an epidemic in China. Moreover, reports indicate that hospitalization risk may be higher for patients infected with the Delta form than the Alpha type. According to a number of studies, vaccinations against symptomatic infection with the Delta variation may be less effective than against other strains, but they are still quite successful in preventing hospitalization and serious illness. You can find more talks about the effectiveness of vaccines against the Delta variant elsewhere [12].

The N501Y mutation in the spike protein is one of the many mutations that the Beta variation, sometimes referred to as the B.1.351 lineage or 20H/501Y.V2, shares with the Alpha variant. The Beta variant was initially discovered in South Africa in late 2020. This variation swiftly overtook other strains in surveillance data from South Africa, indicating possible increased transmissibility. Since then, it has been found in several nations, including the US. This variation has an additional noteworthy mutation, E484K, in the spike protein that may affect immunity from previous infection or vaccination. Research has demonstrated that this mutation can dramatically lower convalescent plasma's antibody neutralization, often by more than ten times. The effects of this mutation, however, change with time and among individuals. It has been demonstrated that adding the B.1.351 lineage spike protein to a viral construct reduces the neutralizing activity of convalescent plasma, with a sizable fraction of plasma samples losing this ability. The majority of samples, however, continued to bind to the Beta spike protein using non-neutralizing antibodies. Although at lower levels than the wild-type virus, plasma from recipients of mRNA COVID-19 vaccinations appears to retain neutralizing action against the Beta variant. Although the clinical significance of these decreases in neutralizing activity is still unknown, protection against the Beta version is probably still going to be provided by mRNA COVID-19 vaccine-induced immunity. Other vaccine options appear to be equally effective against the Beta version, according to preliminary data from trials assessing them; but, in regions where the variant is common, the degree of protection may be reduced. You can find more talks about the effectiveness of vaccines against the Beta form elsewhere [12].

The Gamma variety, often referred to as the P.1 lineage or 20J/501Y.V3, was discovered in four Brazilian tourists in Japan at first, and in December 2020, it made up 42% of the sequenced specimens in the Brazilian state of Amazonas. Several nations, including the US, have reported seeing this variation. It carries many mutations, including three (N501Y, E484K, and K417T) in the spike protein receptor-binding domain, which raises questions regarding possible immune-related effects and increased transmissibility. The B.1.427 and B.1.429 lineages, which together make up the Epsilon variations and are referred to as 20C/S452R or CAL.20C, were initially discovered in Southern California. These mutations had been found in other nations and made up 35% of the viral samples that had been sequenced in California by January 2021. They have many mutations in their spike protein, such as L452R, which results in enhanced cell entrance and decreased susceptibility to neutralization by vaccine recipient and convalescent plasma in vitro. In contrast to the Beta variety, data indicates that the B.1.429 lineage's decreased sensitivity to neutralization is rather small. In comparison to the wild-type virus, these variations are likewise associated with a twofold increase in viral RNA levels on nasal swabs [12].

Transmission:

Geographically, since the first instances were recorded at the end of 2019 in Wuhan, China, COVID-19 has spread to every continent. More than 200 million COVID-19 confirmed cases have been recorded worldwide; the World Health Organization and the European Centre for Disease Prevention and Control provide regular updates on their websites. There's also an interactive map available that shows confirmed cases around the globe. It's crucial to remember, nevertheless, that the published case counts probably underestimate the actual COVID-19 burden. Acute infections frequently go unreported and untreated. According to seroprevalence surveys carried out in the US and Europe, the rate of previous exposure to SARS-CoV-2, as indicated by seropositivity, is estimated to be at least ten times higher than the reported case incidence, even after correcting for possible false positives or negatives [13].

The main way that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spreads is through person-to-person transmission. The main way that this is spread is by close contact, usually between two and six meters, via respiratory particles. These particles can spread to others if they are inhaled or come into touch with mucous membranes after being discharged by an infected person by coughing, sneezing, or talking. Furthermore, respiratory secretions or touching infected surfaces and then touching one's face might contaminate one's hands and spread the infection. Although the primary mechanism of transmission is direct respiratory transmission, SARS-CoV-2 can also travel through the air, especially in enclosed and poorly ventilated settings, and over longer distances. While the exact role of airborne transmission in the pandemic remains unknown, outbreaks in public places such as buses and restaurants have sparked worries. Although the overall transmission rates indicate that aerial transmission is not the dominant modality, experimental tests have confirmed that airborne transmission is feasible [13].

Although SARS-CoV-2 has been found in non-respiratory specimens like blood, ocular secretions, semen, and feces, it is unknown how these specimens are spread. The possibility of the virus spreading through sewage and blood is limited, despite some reports indicating it might be present in these materials. Additionally, there is no proof of vertical transfer during pregnancy or transmission by contact with non-mucous membrane sites. When a person has SARS-CoV-2 infection, their infectiousness lasts for a longer time and peaks early in the illness. After seven to ten days, transmission is less likely, especially in individuals whose immune systems are still functioning, and their illnesses are minor.

Peak Infectious Period: The early phases of COVID-19 disease, when viral RNA levels in upper respiratory specimens are highest, are the most contagious times for infected individuals. According to a modeling study, infectiousness peaked two days prior to and one day following the beginning of symptoms, then started to decline seven days later. In a different investigation, all secondary instances happened to people who saw the index case within six days of the commencement of symptoms [13].

Prolonged Infectiousness Is Not Equivalent to Extended Viral RNA Detection: Age and the severity of the sickness may have an impact on how long viral RNA sheds. Viral RNA can linger in respiratory specimens for up to 18 days after the onset of symptoms, although this does not always mean that an active virus is present. According to studies, infectious viruses are usually undetectable when their quantities of viral RNA fall below a threshold (e.g., <106 copies/mL). Furthermore, it is rare—especially in individuals with moderate disease and resolved symptoms—to isolate infectious viruses from respiratory specimens more than ten days following the onset of symptoms. Even though prolonged viral shedding in immunocompromised people has been reported on occasion, more investigation is required to completely comprehend the clinical significance of these findings [13].

Vulnerability Across Age Groups

While COVID-19 cases have been reported across all age groups, individuals of advanced age appear to be more susceptible to infection. Initial findings indicate that middle-aged individuals were the most affected demographic (refer to Table 2). Conversely, infection rates among children and young adults were notably low, ranging from 0.8% to 4.0%. Furthermore, asymptomatic infection rates are notably high within these age brackets [14] .

Transmission Dynamics and R0

Early reports from China suggest a reproductive number (R0) for COVID-19 ranging from 2.2 to 2.7 days, indicating that the number of infected individuals doubles approximately every 6 to 7 days. This trend is supported by the outbreak on the Diamond Princess Cruise Ship. However, Sanche et al. found a slightly longer serial interval of 5.7 days (95% CI, 3.8–8.9 days). Yuan et al., in a study utilizing real-time reproduction number (Rt), reported Rt values for Italy, Germany, France, and Spain as 3.1, 4.43, 6.56, and 3.95, respectively. Liu et al., in a review of 14 studies, found an average R0 of 3.8 (ranging from 1.4 to 6.49), highlighting variability in R0 estimates even within the same geographic region. This indicates the need for more comprehensive data to determine a more accurate R0 value [15].

Fatality Rate

The overall case fatality rate reported by the WHO as of April 13, 2020, was 6.3%. However, significant disparities in mortality rates exist between countries, as illustrated in Table 3. Mortality rates are notably higher in countries with older populations. In Italy, the median age of COVID-19 fatalities was 78 years, compared to a median patient age of 62. In Turkey, the current case fatality rate stands at 2.1%, highlighting the importance of considering regional variations. Mortality associated with COVID-19 is influenced by various factors, including underlying health conditions, healthcare capacity, and age demographics [16].

Death Rates by Age Group

It is commonly known that advancing age and rising death rates are related. In these age groups, effective COVID-19 prevention strategies have a major impact on national mortality rates. Early reports from China showed that older patients, especially those over 80, had a death rate that might be up to three times greater. ICU death rates were found to be 26% in an Italian study, and they increased to 36% among individuals over 65. Furthermore, there were shorter times between the onset of symptoms and death among older patients, highlighting the need to address this demographic's vulnerability immediately. Italy revealed on April 7, 2020, that 83% of COVID-19-related deaths involved people over the age of 70. According to a study conducted in Korea, the general death rate was 0.9%, but among those 80 years of age and beyond, it spiked to 9.3%. Similar patterns were also noted in the USA [17].

Risk Factors for Mortality and the Progression of Disease

The disease can progress quickly; in patients who are advanced in age, the median survival period can be as low as five days. Hypertension, diabetes mellitus, cardiovascular diseases, and respiratory disorders were shown to be the most common comorbidities in a meta-analysis of 46,248 individuals from eight studies. A higher frequency was noted in cases of severe illness. A different meta-analysis identified the most often found underlying disorders among hospitalized patients as being hypertension, cardiovascular diseases, diabetes mellitus, smoking, chronic obstructive pulmonary disease, cancer, and chronic kidney disease. Preexisting comorbidities increased the fatality rate dramatically, according to a summary analysis from the China CDC: the rate increased by 10.5% for cardiovascular disease, 7.3% for diabetes, 6.3% for chronic respiratory illness, 6.0% for hypertension, and 5.6% for cancer. The most common comorbidities found were hypertension (72%), diabetes mellitus (31.5%), ischemic heart disease (27.4%), and chronic renal failure (23.5%), according to an Italian weekly report on COVID-19 mortality. The proportion of COVID-19 patients who died without comorbidities was only 2.8%. In a combined analysis, people with hypertension had a nearly 2.5-fold increased risk of dying or developing a serious illness, especially if they were older [18].

Conclusion:

In summary, the COVID-19 epidemiology shows a complicated interaction of variables affecting the virus's propagation, severity, and mortality. Age has become a key factor in determining susceptibility and mortality during the pandemic, with older age substantially associated with a higher chance of developing a serious disease and passing away. The majority of COVID-19 deaths have continuously been among the elderly, especially those over 70. This underscores the critical need for focused preventive efforts and healthcare interventions within this population. Comorbidities have also been found to be important risk factors for the development of diseases and unfavorable outcomes. These include respiratory disorders, cardiovascular disorders, diabetes mellitus, and hypertension. These underlying diseases highlight the significance of thorough risk assessment and management measures in COVID-19 care, as they not only raise the probability of severe illness but also contribute to heightened death rates. Estimates of the virus's transmissibility, as indicated by its reproductive number (R0), range from 2.2 to 6.56 depending on the population and environment. The dynamic character of COVID-19 transmission and the necessity of continual surveillance and mitigation attempts to successfully stop its spread are highlighted by the diversity in R0 values. Furthermore, differences in public health responses, socioeconomic conditions, and healthcare infrastructure have been exposed by the global dispersion of COVID-19 cases, leading to disparate outcomes throughout nations and regions. These disparities highlight how crucial it is to handle the pandemic's complex issues with evidence-based therapies, coordinated international cooperation, and fair access to healthcare resources. To sum up, knowledge of the epidemiological dynamics of COVID-19 is essential for developing clinical management plans, influencing public health policy, and lessening the pandemic's effects on communities around the world. To effectively stop the virus's transmission, lower morbidity, and fatality rates, and eventually put an end to the COVID-19 pandemic, more research, surveillance, and cooperation are needed.

References:

1. Gorbalenya, A.E. et al. (2020) severe acute respiratory syndrome related coronavirus: the species and its viruses – a statement of the Coronavirus Study Group. bioRxiv. Published online February 11, 2020. https://doi.org/10.1101/2020.02.07.937862
2. Resta, S. et al. (2018) Isolation and propagation of a human enteric coronavirus. Science 4717, 978–981.
3. Cohen, J. et al. (2019) New SARS-like virus in China triggers alarm. Science 6475, 234–235.
4. Fung, T. S., & Liu, D. X. (2019). Human coronavirus: host-pathogen interaction. Annual review of microbiology, 73, 529-557.
5. Li, Q. et al. (2020) Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. N. Engl. J. Med. Published online January 29, 2020. https://doi.org/10.1056/NEJMoa2001316
6. Wang, D. et al. (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. Published online February 7, 2020. https://doi.org/10.1001/jama.2020.1585

7. Chan, J.F-W. et al. (2020) A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 395, 514–523.

8. Yang, Y. et al. (2020) Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China. medRxiv. Published online February 21, 2020. https://doi.org/10.1101/2020.02.10.20021675

9. Chang, D. et al. (2020) Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan, China. JAMA. Published online February 7, 2020. https://doi.org/10.1001/jama.2020.1623

10. Chen, N. et al. (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395, 507–513.

11. Holshue, M.L. et al. (2020) First case of 2019 novel coronavirus in the United States. N Engl. J. Med. Published online January 31, 2020. https://doi.org/10.1016/S1473-3099(20)30067-0

12. McIntosh, K., Hirsch, M. S., & Bloom, A. (2021). COVID-19: Epidemiology, virology, and prevention. UpToDate. Available online: https://www. uptodate. com/contents/covid-19-epidemiology-virology-and-prevention (accessed on 18 March 2021).

13. Bulut, C., & Kato, Y. (2020). Epidemiology of COVID-19. Turkish journal of medical sciences, 50(9), 563-570.

14. Li Q, Guan X, Wu P, Wang W, Zhou L et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. The New England Journal of Medicine 2020; 382 (13): 1199-1207. doi:10.1056/NEJMoa2001316

15. Zhang S, Diao M, Yu W, Pei L, Lin Z et al. Estimation of the reproductive number of novel coronavirus (COVID-19) and the probable outbreak size on the Diamond Princess cruis ship: a data-driven analysis. International Journal of Infection Diseases 2020; 93: 201-204. doi: 10.1016/j.ijid.2020.02.033

16. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020; April 6, [Epub ahead of print]. doi:10.1001/jama.2020.5394

17. Lippi G, Wong J, Henry BM. Hypertension and its severity or mortality in coronavirus disease 2019 (COVID-19): a pooled analysis. Polish Archives of Internal Medicine 2020; March 31, [Epub ahead of print]. doi: 10.20452/pamw.15272

18. Emami A, Javanmardi F, Pirbonyeh N, Akbari A. Prevalence of underlying diseases in hospitalized patients with COVID-19: a systematic review and meta-analysis. Archieves of Academic Emergency Medicine 2020; 8 (1): e35.